Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moiety
The present invention provides methods comprising the in vivo delivery of small nucleic acid molecules capable of mediating RNA interference and reducing the expression of myostatin, wherein the small nucleic acid molecules are introduced to a subject by systemic administration. Specifically, the invention relates to methods comprising the in vivo delivery of short interfering nucleic acid (siNA) molecules that target a myostatin gene expressed by a subject, wherein the siNA molecule is conjugated to a lipophilic moiety, such as cholesterol. The myostatin siNA conjugates that are delivered as per the methods disclosed are useful to modulate the in vivo expression of myostatin, increase muscle mass and/or enhance muscle performance. Use of the disclosed methods is further indicated for treating musculoskeletal diseases or disorders and/or diseases or disorders that result in conditions in which muscle is adversely affected.
1. A double-stranded short interfering nucleic acid (siNA) molecule that inhibits the expression of myostatin, wherein:
(a) the siNA molecule comprises a sense strand and an antisense strand;
(b) each strand is independently 19 to 30 nucleotides in length; and
(c) the antisense strand comprises the nucleotide sequence of:
(SEQ ID NO: 19)
5′-AUAUUAUUUGUUCUUUGCC-3′,
and wherein the siNA molecule comprises one or more chemically modified nucleotides.
2. The double-stranded siNA molecule of claim 1 , wherein the siNA molecule comprises:
(SEQ ID NO: 2)
5′-GGCAAAGAACAAAUAAUAU-3′
and
(SEQ ID NO: 19)
5′-AUAUUAUUUGUUCUUUGCC-3′,
and wherein the siNA molecule comprises one or more chemically modified nucleotides.
3. The double-stranded siNA molecule of claim 2 , wherein the siNA molecule is linked to a lipophilic moiety.
4. The double-stranded siNA molecule of claim 3 , wherein the lipophilic moiety is cholesterol.
5. The double-stranded siNA molecule of claim 4 , wherein the lipophilic moiety is attached to a 3′-end of the siNA molecule.
6. The double-stranded siNA molecule of claim 4 , wherein the lipophilic moiety is attached to a 5′-end of the siNA molecule.
7. The double-stranded siNA molecule of claim 2 , which comprises one or more 3′-overhanging nucleotides on one or both strands.
8. The double-stranded siNA molecule of claim 1 , wherein the siNA molecule is linked to a lipophilic moiety.
9. The double-stranded siNA molecule of claim 8 , wherein the lipophilic moiety is cholesterol.
10. The double-stranded siNA molecule of claim 8 , wherein the lipophilic moiety is attached to a 3′-end of the siNA molecule.
11. The double-stranded siNA molecule of claim 8 , wherein the lipophilic moiety is attached to a 5′-end of the siNA molecule.
12. The double-stranded siNA molecule of claim 1 , which comprises one or more 3′-overhanging nucleotides on one or both strands.